LOBE SCIENCES ANNOUNCES CAD$23,000,000 SALE OF COWLITZ CANNABIS OPTION TO IONIC BRANDS CORP. December 1, 2020 Vancouver, British Columbia – Lobe Sciences Ltd. (“Lobe” or
Benjamin Kelmendi, MD
Benjamin is a psychiatrist and an Associate Professor in the Department of Psychiatry at the Yale University School of Medicine. His primary clinical expertise is in PTSD, Depression, OCD, and the endocannabinoid system. He is the co-founder of the Yale Psychedelic Science Group. He leads a research program focused on the therapeutic potential of psychedelic medicines, across a range of psychiatric diagnoses. He is currently investigating the effects of psilocybin on the neurocircuitry implicated in the development, maintenance, and treatment of patients with OCD. He is also exploring the effects of MDMA on brain activation and neural network organization in PTSD to understand the relationship between MDMA-induced neural changes and the acute cognitive and behavioral effects of the drug.